The biliary duct is an extremely rare site for colon cancer metastasis. It often leads to a diagnostic dilemma, since primary cholangiocarcinoma (potentially treatable with surgery) has a similar presentation. This paper highlights our experience with 5 consecutive patients who had colon malignancy with biliary metastasis, and prognosis of their disease. Five patients, with a history of primary colon cancer since 2010, were identified to have biliary metastasis. Of these, 4 (80.0%) patients were male. The median time to diagnosis of biliary metastasis from diagnosis of colon cancer was 59.2 months (0-70.1 months), and all exhibited symptoms of biliary obstruction or its associated complications. Evaluation of the tumour samples revealed all specimens to be negative for CK7 but positive for CK20, suggestive of a colorectal primary. The median survival of the 5 patients was 23.5 months (1.8-44.5 months) from the diagnosis of biliary metastasis. However, none of their death was related to the direct complication of biliary obstruction. Biliary metastasis is a rare entity for metastatic colon malignancy. Diagnosis may be difficult radiologically, and immunohistochemical staining may help in identification. The overall survival for these patients is dismal. (Ann Hepatobiliary Pancreat Surg 2017;21:57-60)
INTRODUCTION
Metastasis to the bile duct is an extremely rare manifestation of colon cancer. 1, 2 Due to its rarity, the symptoms, best modality of investigations, and prognosis are not clear. This study therefore aims to review our institution's experience in managing 5 patients with biliary metastasis.
This was a retrospective review from a single institution. All patients were above the age of 21, and were diagnosed with biliary metastasis, secondary to a colonic primary detected in 2010. Biliary metastases were confirmed using histopathological methods; immunohistochemistry confirmed the colonic primary.
Patients were identified using a pre-existing colorectal cancer database. Details of the cases, including patient demographics, histopathological characteristics, investigation details, and oncological progress, were collected.
CASE

Patient demographics
Biliary metastatic adenocarcinoma was histologically diagnosed in 5 patients, who had a prior history of primary colon cancer since 2010. The median age of diagnosis of colon cancer for these patients was 57 years (49-78 years). Family history of colorectal malignancy was negative for all 5 patients. Demographics of all patients are provided in Table 1 .
The median time from diagnosis of colon cancer to biliary metastasis was 59.2 months (0-70.1 months). All patients presented with symptoms and biochemical outcomes for obstructive jaundice or persistent unresolved transaminitis. Prior to the development of biliary metastasis, the primary colonic tumour had been resected in Fig. 1 depicts how the intra-and extra-hepatic biliary ductal dilation secondary to a biliary stricture mimics the radiological appearance of a primary cholangiocarcinoma. Also, with imaging using magnetic resonance cholangiopancreaticogram (MRCP), the endoluminal biliary metastasis at the confluence of the right and left hepatic ducts can be easily mistaken as cholangiocarcinoma ( Fig.   1) , thus highlighting the difficulty in differentiating both pathologies using only radiological investigations.
Radiological appearance
Malignant characteristics
Tumours resected from all 5 patients Immunohistochemical staining for biliary brushings from tumours of all 5 patients were positive for CK20, but negative for CK7.
Three samples assessed for CDX2 were positive. Our study also showed that prognosis after the development of biliary metastasis from colorectal cancer is poor.
Surgical and oncological outcomes
The 5-year survival from the time of biliary metastasis is dismal at 0%, with the median time of death being approximately 2 years (0.6-3.1 years). Our result is similar to those reported at the Sloan-Kettering Cancer Centre, where the 5-year survival rates for unresected biliary metastasis is 0%. 15 Patients who develop biliary metastasis also suffer significant morbidity with repeated episodes of hepatobiliary sepsis due to biliary obstruction, requiring admission, antibiotics and invasive procedures like PTC and drainage, or ERCP with stent insertion, which carries further procedural risks like pancreatitis, stent related complications like blockage, and even duodenal perforation.
Therefore, it is essential that clinicians bear in mind that a presentation of obstructive jaundice in patients with a prior history of colon malignancy has the possibility of developing biliary metastasis, even though it is extremely rare. This will enable the clinician to utilize immunohistochemical stains as part of the diagnostic work-up. This is particularly important as the management and prognosis of cholangiocarcinoma and biliary metastasis is markedly different, and would affect the approach for subsequent counselling.
In conclusion, though rare, biliary metastasis must remain a differential when reviewing a patient presenting with painless jaundice, having prior history of colon malignancy. Immunohistochemical tests may be necessary to differentiate it from primary cholangiocarcinoma.
However, development of biliary metastasis confers a poor outcome in terms of survival.
